Use and Effectiveness of Adjuvant Chemotherapy for Stage III Colon Cancer: A Population-Based Study

2016 ◽  
Vol 14 (1) ◽  
pp. 47-56 ◽  
Author(s):  
Christopher M. Booth ◽  
Sulaiman Nanji ◽  
Xuejiao Wei ◽  
Yingwei Peng ◽  
James J. Biagi ◽  
...  
Keyword(s):  
Colon Cancer ◽  
Adjuvant Chemotherapy ◽  
Population Based ◽  
Stage Iii ◽  
Population Based Study ◽  
Stage Iii Colon Cancer

scholarly journals Impact of timing of adjuvant chemotherapy on survival in stage III colon cancer: a population-based study

BMC Cancer ◽  
2018 ◽  
Vol 18 (1) ◽  
Author(s):  
Peng Gao ◽  
Xuan-zhang Huang ◽  
Yong-xi Song ◽  
Jing-xu Sun ◽  
Xiao-wan Chen ◽  
...  
Keyword(s):  
Colon Cancer ◽  
Adjuvant Chemotherapy ◽  
Population Based ◽  
Stage Iii ◽  
Population Based Study ◽  
Stage Iii Colon Cancer

scholarly journals Use of adjuvant chemotherapy in patients with stage III colon cancer in Puerto Rico: A population-based study

PLoS ONE ◽  
2018 ◽  
Vol 13 (3) ◽  
pp. e0194415 ◽  
Author(s):  
Karen J. Ortiz-Ortiz ◽  
Guillermo Tortolero-Luna ◽  
Ruth Ríos-Motta ◽  
Alejandro Veintidós-Feliú ◽  
Robert Hunter-Mellado ◽  
...  
Keyword(s):  
Colon Cancer ◽  
Puerto Rico ◽  
Adjuvant Chemotherapy ◽  
Population Based ◽  
Stage Iii ◽  
Population Based Study ◽  
Stage Iii Colon Cancer

Effect of age on survival benefit of adjuvant chemotherapy in elderly stage III colon cancer patients: a population-based analysis

2008 ◽  
Vol 26 (15_suppl) ◽  
pp. 4014-4014 ◽  
Author(s):  
I. H. Zuckerman ◽  
A. J. Davidoff ◽  
E. Onukwugha ◽  
N. Pandya ◽  
J. F. Gardner ◽  
...  
Keyword(s):  
Colon Cancer ◽  
Adjuvant Chemotherapy ◽  
Cancer Patients ◽  
Survival Benefit ◽  
Population Based ◽  
Stage Iii ◽  
Stage Iii Colon Cancer ◽  
Effect Of Age

Risk Factors for Financial Hardship in Patients Receiving Adjuvant Chemotherapy for Colon Cancer: A Population-Based Exploratory Analysis

2012 ◽  
Vol 30 (14) ◽  
pp. 1608-1614 ◽  
Author(s):  
Veena Shankaran ◽  
Sanjay Jolly ◽  
David Blough ◽  
Scott D. Ramsey
Keyword(s):  
Colon Cancer ◽  
Adjuvant Chemotherapy ◽  
Significant Proportion ◽  
Population Based ◽  
Exploratory Analysis ◽  
Financial Hardship ◽  
Stage Iii ◽  
Factors Associated ◽  
Stage Iii Colon Cancer ◽  
Younger Age

PurposeCharacteristics that predispose patients to financial hardship during cancer treatment are poorly understood. We therefore conducted a population-based exploratory analysis of potential factors associated with financial hardship and treatment nonadherence during and following adjuvant chemotherapy for colon cancer.Patients and MethodsPatients diagnosed with stage III colon cancer between 2008 and 2010 were identified from a population-based cancer registry representing 13 counties in Washington state. Patients were asked to complete a comprehensive survey on treatment-related costs. Patients were considered to have experienced financial hardship if they accrued debt, sold or refinanced their home, borrowed money from friends or family, or experienced a 20% or greater decline in their annual income as a result of treatment-related expenses. Logistic regression analysis was used to investigate factors associated with financial hardship and treatment nonadherence.ResultsA total of 284 responses were obtained from 555 eligible patients (response rate, 51.2%). Nearly all patients in the final sample were insured during treatment. In this sample, 38% of patients reported one or more financial hardships as a result of treatment. The factors most closely associated with treatment-related financial hardship were younger age and lower annual household income. Younger age, lower income, and unemployment or disability (which occurred in most instances following diagnosis) were most closely associated with treatment nonadherence.ConclusionA significant proportion of patients undergoing adjuvant chemotherapy for stage III colon cancer may experience financial hardship, despite having health insurance coverage. Interventions to help at-risk patients early on during therapy may prevent long-term financial adverse effects.

Time trends in chemotherapy (administration and costs) and relative survival in stage III colon cancer patients – a large population-based study from 1990 to 2008

2012 ◽  
Vol 52 (5) ◽  
pp. 941-949 ◽  
Author(s):  
Colette B. M. van den Broek ◽  
Esther Bastiaannet ◽  
Jan Willem T. Dekker ◽  
Johanneke E. A. Portielje ◽  
Anton J. M. de Craen ◽  
...  
Keyword(s):  
Colon Cancer ◽  
Cancer Patients ◽  
Time Trends ◽  
Large Population ◽  
Relative Survival ◽  
Population Based ◽  
Stage Iii ◽  
Population Based Study ◽  
Stage Iii Colon Cancer ◽  
Chemotherapy Administration

scholarly journals Adherence to Clinical Practice Guidelines and Colorectal Cancer Survival: A Retrospective High-Resolution Population-Based Study in Spain

2020 ◽  
Vol 17 (18) ◽  
pp. 6697
Author(s):  
Francisco Carrasco-Peña ◽  
Eloisa Bayo-Lozano ◽  
Miguel Rodríguez-Barranco ◽  
Dafina Petrova ◽  
Rafael Marcos-Gragera ◽  
...  
Keyword(s):  
Colorectal Cancer ◽  
Colon Cancer ◽  
Clinical Practice ◽  
Adjuvant Chemotherapy ◽  
High Resolution ◽  
Clinical Practice Guidelines ◽  
Practice Guidelines ◽  
Population Based ◽  
Population Based Study ◽  
Stage Iii Colon Cancer

Colorectal cancer (CRC) is the third most common cancer worldwide. Population-based, high-resolution studies are essential for the continuous evaluation and updating of diagnosis and treatment standards. This study aimed to assess adherence to clinical practice guidelines and investigate its relationship with survival. We conducted a retrospective high-resolution population-based study of 1050 incident CRC cases from the cancer registries of Granada and Girona, with a 5-year follow-up. We recorded clinical, diagnostic, and treatment-related information and assessed adherence to nine quality indicators of the relevant CRC guidelines. Overall adherence (on at least 75% of the indicators) significantly reduced the excess risk of death (RER) = 0.35 [95% confidence interval (CI) 0.28–0.45]. Analysis of the separate indicators showed that patients for whom complementary imaging tests were requested had better survival, RER = 0.58 [95% CI 0.46–0.73], as did patients with stage III colon cancer who underwent adjuvant chemotherapy, RER = 0.33, [95% CI 0.16–0.70]. Adherence to clinical practice guidelines can reduce the excess risk of dying from CRC by 65% [95% CI 55–72%]. Ordering complementary imagining tests that improve staging and treatment choice for all CRC patients and adjuvant chemotherapy for stage III colon cancer patients could be especially important. In contrast, controlled delays in starting some treatments appear not to decrease survival.

Sign in / Sign up

Export Citation Format

Share Document